These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23281926)

  • 21. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
    Stohl W
    Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab.
    Kowalczyk-Quintas C; Chevalley D; Willen L; Jandus C; Vigolo M; Schneider P
    Front Immunol; 2018; 9():2698. PubMed ID: 30524439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus.
    Atisha-Fregoso Y; Toz B; Diamond B
    J Clin Invest; 2021 Jun; 131(12):. PubMed ID: 34128474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between early immunophenotypic changes and therapeutic response of belimumab in patients with systemic lupus erythematosus.
    Hirano A; Fujioka K; Kida T; Omura S; Sofue H; Sakashita A; Sagawa T; Isoda Y; Kasahara A; Sagawa R; Fujii W; Seno T; Wada M; Kohno M; Kawahito Y
    Lupus; 2023 Jan; 32(1):63-73. PubMed ID: 36317306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
    Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
    Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BAFF and selection of autoreactive B cells.
    Liu Z; Davidson A
    Trends Immunol; 2011 Aug; 32(8):388-94. PubMed ID: 21752714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians.
    Sanchez-Niño MD; Ortiz A
    Nephrol Dial Transplant; 2015 Mar; 30(3):394-400. PubMed ID: 24914092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
    Poh YJ; Baptista B; D'Cruz DP
    Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).
    Stohl W
    Expert Rev Clin Immunol; 2017 Jun; 13(6):623-633. PubMed ID: 28164726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.
    Fairfax K; Mackay IR; Mackay F
    IUBMB Life; 2012 Jul; 64(7):595-602. PubMed ID: 22641424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?
    Stohl W
    Curr Rheumatol Rep; 2012 Aug; 14(4):303-9. PubMed ID: 22547203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.
    Nakayama Y; Kosek J; Capone L; Hur EM; Schafer PH; Ringheim GE
    J Immunol; 2017 Oct; 199(7):2388-2407. PubMed ID: 28848067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B cell alterations during BAFF inhibition with belimumab in SLE.
    Ramsköld D; Parodis I; Lakshmikanth T; Sippl N; Khademi M; Chen Y; Zickert A; Mikeš J; Achour A; Amara K; Piehl F; Brodin P; Gunnarsson I; Malmström V
    EBioMedicine; 2019 Feb; 40():517-527. PubMed ID: 30593436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigations of a rabbit (Oryctolagus cuniculus) model of systemic lupus erythematosus (SLE), BAFF and its receptors.
    Yang J; Pospisil R; Ray S; Milton J; Mage RG
    PLoS One; 2009 Dec; 4(12):e8494. PubMed ID: 20041151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment.
    Zhang M; Lee F; Knize A; Jacobsen F; Yu S; Ishida K; Miner K; Gaida K; Whoriskey J; Chen C; Gunasekaran K; Hsu H
    Clin Exp Rheumatol; 2019; 37(6):906-914. PubMed ID: 30789152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus.
    Garcia A; De Sanctis JB
    Curr Pharm Des; 2016; 22(41):6306-6312. PubMed ID: 27587201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Belimumab: targeted therapy for lupus.
    Chugh PK; Kalra BS
    Int J Rheum Dis; 2013 Feb; 16(1):4-13. PubMed ID: 23441766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.